RYTM Company Profile and Key Details

Q: Who are the executives of RYTM?

Mr. Hunter C. Smith M.B.A.Chief Financial Officer & TreasurerMs. Jennifer L. ChienExecutive Vice President & Head of North AmericaMr. Joseph ShulmanChief Technical OfficerDr. David P. Meeker M.D.Chairman, Pres & Chief Executive OfficerMr. David ConnollyHead of Investor Relations & Corporation CommunicationsMr. Christopher GermanCorporation Controller, Principal Accounting Officer & Executive DirectorMr. Yann MazabraudExecutive Vice President & Head of InternationalMs. Pamela J. CramerChief HR OfficerMr. Jim FlahertySenior Vice President & Gen. CounselMs. Sarah RyanVice President of Sales & MarketingMr. William T. RobertsChief Accounting Officer

NASDAQ : RYTM

Rhythm Pharmaceuticals

$88.96

0.2743+0.31%

Open: 12:50 PM

60.71

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Rhythm Pharmaceuticals, Inc. (RYTM) stock surged +0.31%, trading at $88.96 on NASDAQ, up from the previous close of $88.69. The stock opened at $88.95, fluctuating between $88.26 and $90.52 in the recent session.

Stock Snapshot

88.69

Prev. Close

6.07B

Market Cap

88.26

Day Low

-28.61

P/E Ratio

-3.11

EPS (TTM)

-2.32

Cash Flow per Share

88.95

Open

68.29M

Number of Shares

90.515

Day High

82.51%

Free Float in %

2.87

Book Value

155.93K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2026	89.76	90.51	86.60	88.69	660.99K
Apr 16, 2026	88.44	90.79	87.21	88.11	731.49K
Apr 14, 2026	86.93	88.41	86.16	87.28	520.51K
Apr 13, 2026	83.96	87.61	83.96	86.81	507.33K
Apr 10, 2026	86.17	86.27	82.96	84.39	379.09K
Apr 09, 2026	85.29	88.64	84.45	86.13	604.25K
Apr 08, 2026	89.99	90.10	84.96	85.48	981.64K
Apr 07, 2026	86.82	86.99	83.89	86.66	747.59K
Apr 06, 2026	85.97	88.79	85.97	86.96	535.14K
Apr 02, 2026	85.81	88.64	85.74	86.29	546.43K
Apr 01, 2026	87.87	90.80	87.18	88.12	945.56K
Mar 31, 2026	78.99	87.07	78.38	86.97	1.96M
Mar 30, 2026	75.76	77.59	74.50	77.25	1.26M
Mar 27, 2026	81.00	83.65	75.44	75.82	1.42M
Mar 25, 2026	82.60	84.85	80.99	84.62	1.15M
Mar 24, 2026	83.07	83.75	80.70	82.59	890.39K
Mar 23, 2026	90.42	91.12	83.53	84.65	997.32K
Mar 20, 2026	96.71	100.00	86.54	87.45	3.18M
Mar 19, 2026	84.71	90.53	84.00	90.31	993.69K
Mar 18, 2026	86.21	87.26	84.02	85.86	846.5K

Contact Details

Boston, MA 02116

United States

https://www.rhythmtx.com 857 264 4280

About Company

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstr�m syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) closed at $88.96 USD, gaining $0.27 (0.31%) from the previous close of $88.69. The stock is currently mid-range between its 52-week high and low $55.31 and $122.20. With a market capitalization of about $6.07 billion, Rhythm Pharmaceuticals, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.14). Key stats such as the average daily volume over the past year has been around 828.72 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Rhythm Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Meeker, the company employs approximately 283 people and listed since October 09, 2017. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -3.73%, SMA50 -6.48%, SMA200 4.54%). The stock’s 14-day RSI is 43.68 (neutral), while the ATR of 5.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.75% below its high and over 113.64% above its low. Average 10-day trading volume of 559.88 thousand shares is below the 3-month average of 828.48 thousand, indicating normal recent market interest.

Valuation Metrics

Rhythm Pharmaceuticals, Inc. trades at a P/E ratio of -30.18, slightly below the S&P 500 average, with a price-to-sales ratio of 31.92 and a price-to-book ratio of 42.65 reflecting a rich premium to book value. The P/FCF stands at -51.93, also below market averages. Compared to sector medians, Rhythm Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Rhythm Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$24.16. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Rhythm Pharmaceuticals, Inc. generated EPS of -$3.10 over the past year. Five-year average earnings growth is -2.34%. The latest quarter delivered EPS of -$0.82. The next quarter is forecast at -$0.80. Next year's EPS is expected at $30.68. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 32 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $176.00 to $72.00. The high target offers 98.44% upside. The low target suggests -18.82% downside. The mean target is $127.62. This offers 43.89% upside. Rhythm Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 15.8%. The prior quarter beat by 13.64%. Over the last six quarters, Apple has recorded several small beats. These include -21.43% in August 06, 2024.

Shareholding & Insider Activity

Rhythm Pharmaceuticals, Inc. has 66.42 million shares outstanding. The public float is 54.80 million shares, elevated short interest at 9.03% of float. This equals 4.67 million shares. The short ratio is 7.76 days. Institutional investors hold 109.83% of the float. Insiders own 0.81%. RA CAPITAL MANAGEMENT, L.P. holds 4.36 million shares, Foley Todd has 909.26 thousand shares and Meeker David P has 201.82 thousand shares. Over the past six months, insider transactions show net selling. They sold 52.96 thousand shares across 14 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Rhythm Pharmaceuticals generated $77.43M in revenue, or $1.34 per share. Gross margin was 87.99%, operating margin -238.10%, and net profit margin -238.52%. Returns are negative, with ROA at -55.50% and ROE at -108.79%.
On valuation metrics, Rhythm Pharmaceuticals trades at a P/E of -30.18, P/S of 31.92 and P/B of 42.65. The current ratio is 4.41 and quick ratio is 4.16. Operationally, the company’s inventory turnover is 0.76 and cash conversion cycle is 271.24 days. Debt-to-equity is 1.77, supported by a cash flow-to-debt ratio of -0.47.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Rhythm Pharmaceuticals posted revenue of $77.43M, down slightly from $23.64M in the prior quarter. Gross profit was $68.13M (margin 87.99%). Operating income was - $184.36M (margin -238.1%). Net income was- $184.68M (EPS - $3.20).
The company ended the quarter with $275.85M in cash and short-term investments, a total debt of $1.26M, and net debt of - $58.82M. Total assets were $332.75M, with equity of $169.76M. Financials further reflected weakness, with operating cash flow of - $136.16M, free cash flow of - $136.20M, and capital expenditures of - $47.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Rhythm Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.64%, with price expected at $89.26 by May 01, 2026, within a range of $86.33 to $92.25 3-Month Outlook: Projected rise of 14.18%, reaching $101.27 by July 16, 2026, with a range of $99.81 to $102.72. 1-Year Outlook: Projected gain of 38.08%, with price at $122.46 by April 16, 2027, within a range of $118.63 to $125.90.

Key Takeaways

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shares are flat -4.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Rhythm Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -30.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $87.96, suggesting -0.82% downside. Our AI forecast model points to short-term strength (0.64% over two weeks), a medium-term rise (14.18% over three months), and a longer-term gain (38.08% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Rhythm Pharmaceuticals, Inc. (RYTM) stock price?

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock price is $88.96 in the last trading session. During the trading session, RYTM stock reached the peak price of $90.52 while $88.26 was the lowest point it dropped to. The percentage change in RYTM stock occurred in the recent session was 0.31% while the dollar amount for the price change in RYTM stock was $0.27.

RYTM's industry and sector of operation?

The NASDAQ listed RYTM is part of Biotechnology industry that operates in the broader Healthcare sector. Rhythm Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RYTM?

Mr. Hunter C. Smith M.B.A.
Chief Financial Officer & Treasurer
Ms. Jennifer L. Chien
Executive Vice President & Head of North America
Mr. Joseph Shulman
Chief Technical Officer
Dr. David P. Meeker M.D.
Chairman, Pres & Chief Executive Officer
Mr. David Connolly
Head of Investor Relations & Corporation Communications
Mr. Christopher German
Corporation Controller, Principal Accounting Officer & Executive Director
Mr. Yann Mazabraud
Executive Vice President & Head of International
Ms. Pamela J. Cramer
Chief HR Officer
Mr. Jim Flaherty
Senior Vice President & Gen. Counsel
Ms. Sarah Ryan
Vice President of Sales & Marketing
Mr. William T. Roberts
Chief Accounting Officer

How RYTM did perform over past 52-week?

RYTM's closing price is 60.35% higher than its 52-week low of $55.31 where as its distance from 52-week high of $122.20 is -27.42%.

How many employees does RYTM have?

Number of RYTM employees currently stands at 283.

Link for RYTM official website?

Official Website of RYTM is: https://www.rhythmtx.com

How do I contact RYTM?

RYTM could be contacted at phone 857 264 4280 and can also be accessed through its website. RYTM operates from 222 Berkeley Street, Boston, MA 02116, United States.

How many shares of RYTM are traded daily?

RYTM stock volume for the day was 155.93K shares. The average number of RYTM shares traded daily for last 3 months was 828.72K.

What is the market cap of RYTM currently?

The market value of RYTM currently stands at $6.07B with its latest stock price at $88.96 and 68.29M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	283
Beta	2.15
Sales or Revenue	$77.43M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RYTM Company Profile and Key Details

Rhythm Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways